Claritev Corp (NYSE:CTEV) issued a statement Monday in response to reports of a DOJ criminal antitrust investigation. The stock plummeted 53% over the past week, trading at $16.75.
In August 2024, the company received a confidential grand jury subpoena from the DOJ's Antitrust Division regarding a health insurance probe. Claritev says it has cooperated fully and has not been named a target.
Claritev also reported strong Q1 2026 earnings: revenue reached $244.7 million, up 5.8% year-over-year.












